RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Shandong Cancer Hospital and Institute; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07062055, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Unresectable HCC, BCLC Stage C according to the BCLC strategy-2026 update, with staging established via biopsy pathology and/or clinical diagnosis.

    Inclusion criterion 2

  3. Received targeted-immunotherapy for HCC (e.g., PD-(L)1 inhibitors + tyrosine kinase inhibitors (TKIs))

    Exclusion criterion 13

    Prior immunotherapy: anti-PD-(L)1/CTLA-4 or chimeric antigen receptor T-cell therapy

    Exclusion criterion 14

  4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤5 × upper limit of normal (ULN); total bilirubin <3 × ULN; serum albumin ≥28 g/L

    Inclusion criterion 18

    Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min

    Inclusion criterion 19

    International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN

    Inclusion criterion 21

  5. ≥1 measurable lesion (per RECIST 1.1):

    Inclusion criterion 9

    Tumor: ≥10 mm (CT long axis)

    Inclusion criterion 10

    Lymph node: ≥15 mm (CT short axis)

    Inclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07062055, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male or female patients aged between 18 and 70 years.
  • Unresectable HCC, BCLC Stage C according to the BCLC strategy-2026 update, with staging established via biopsy pathology and/or clinical diagnosis.
  • Child-Pugh class A without clinically significant hepatic decompensation; Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Metastatic burden and local therapy eligibility
  • Extrahepatic oligometastatic disease defined as ≤3 involved organs with ≤5 total metastatic lesions
  • All intended intrahepatic and/or extrahepatic SBRT targets must satisfy protocol-specified target-coverage, liver reserve, and organ-at-risk (OAR) constraints within a composite 5-fraction plan
  • Prognosis \& measurable disease
  • Life expectancy ≥3 months
  • ≥1 measurable lesion (per RECIST 1.1):
  • Tumor: ≥10 mm (CT long axis)
  • Lymph node: ≥15 mm (CT short axis)
  • Prior therapy
  • Prior locoregional therapy permitted:radiofrequency ablation (RFA), TACE, or HAIC, provided that:
  • Documented radiographic progression or intolerance after the prior therapy
  • Washout ≥28 days
  • Treatment-related toxicities recovered to ≤Grade 1 (alopecia and peripheral neuropathy ≤Grade 2 allowed)
  • Laboratory and virologic requirements
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤5 × upper limit of normal (ULN); total bilirubin <3 × ULN; serum albumin ≥28 g/L
  • Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min
  • Urine dipstick protein <2+; if baseline dipstick proteinuria is ≥2+, 24-hour urinary protein must be <1 g
  • International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN

Exclusion Criteria:

  • Histopathological exclusions
  • Mixed HCC subtypes: Fibrolamellar HCC or sarcomatoid HCC or cholangiocarcinoma components
  • Curative local therapy candidacy
  • Current candidacy for resection, liver transplant, or RFA
  • RT infeasibility
  • Prior radioembolization
  • Single liver tumor ≥15 cm or total intrahepatic tumor diameter ≥20 cm
  • more than 5 discrete intrahepatic parenchymal foci are present
  • direct tumor extension into the stomach, duodenum, small bowel, or large bowel
  • measurable common or main-branch biliary duct involvement
  • Prior liver radiotherapy that would result in excessive overlap with the planned treatment fields
  • Prior systemic therapies
  • Received targeted-immunotherapy for HCC (e.g., PD-(L)1 inhibitors + tyrosine kinase inhibitors (TKIs))
  • Prior immunotherapy: anti-PD-(L)1/CTLA-4 or chimeric antigen receptor T-cell therapy
  • Hemorrhage/portal hypertension and hepatic decompensation risk
  • Variceal bleeding within 6 months.
  • Untreated or high-risk esophagogastric varices (e.g., grade ≥2 on endoscopy within 3 months) or other clinical evidence of portal hypertension with high bleeding risk per investigator.
  • Moderate or severe ascites
  • History of or active hepatic encephalopathy
  • History of hemoptysis (≥2.5 mL of bright red blood per episode) within 28 days before study treatment
  • Evidence of bleeding diathesis or significant coagulopathy
  • Current or recent (within 10 days before study treatment) use of aspirin (≥325 mg/day), dipyridamole, ticlopidine, clopidogrel, cilostazol, or therapeutic-dose oral/parenteral anticoagulants or thrombolytic agents
  • Allergy to any component of iparomlimab/tuvonralimab or bevacizumab
  • Comorbidities
  • Active autoimmune disease or a history of autoimmune or inflammatory disease that may relapse; exceptions include hypothyroidism controlled with hormone replacement only, controlled celiac disease, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia)
  • Any condition requiring systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days before study treatment
  • Active or uncontrolled infection, including tuberculosis, or known HIV infection
  • Prior allogeneic stem cell transplantation or organ transplantation
  • Inadequately controlled hypertension, defined as systolic blood pressure ≥150 mmHg and/or diastolic blood pressure >90 mmHg despite optimal medical management, or a history of hypertensive crisis or hypertensive encephalopathy
  • History within 6 months before study treatment of myocardial infarction, unstable angina, symptomatic heart failure (New York Heart Association class ≥II), cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other serious thromboembolic events
  • Major surgical procedure within 28 days before study treatment, or serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
  • History within 6 months before study treatment of gastrointestinal perforation, abdominal or tracheoesophageal fistula, or intra-abdominal abscess

Quoted from ClinicalTrials.gov, NCT07062055, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07062055, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07062055